Allogene Therapeutics (ALLO) Set to Announce Quarterly Earnings on Thursday

Allogene Therapeutics (NASDAQ:ALLO) will issue its quarterly earnings data after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.34) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Allogene Therapeutics (NASDAQ:ALLO) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.03. Allogene Therapeutics had a negative net margin of 223,139.98% and a negative return on equity of 50.24%. On average, analysts expect Allogene Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Allogene Therapeutics Price Performance

Allogene Therapeutics stock opened at $2.99 on Wednesday. Allogene Therapeutics has a fifty-two week low of $2.01 and a fifty-two week high of $5.78. The firm’s 50 day simple moving average is $2.70 and its 200-day simple moving average is $2.66. The company has a market cap of $625.24 million, a P/E ratio of -1.86 and a beta of 0.84.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Truist Financial reissued a “buy” rating and set a $14.00 target price (down from $17.00) on shares of Allogene Therapeutics in a research note on Friday, August 9th. HC Wainwright reissued a “buy” rating and issued a $9.00 price objective on shares of Allogene Therapeutics in a research note on Wednesday, October 30th. Oppenheimer initiated coverage on Allogene Therapeutics in a research report on Thursday, August 8th. They set an “outperform” rating and a $11.00 price objective for the company. Citigroup upped their target price on Allogene Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a report on Friday, August 9th. Finally, Canaccord Genuity Group decreased their price target on shares of Allogene Therapeutics from $35.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Allogene Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $9.96.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).